ClinicalTrials.gg
RecruitingNCT07723144Updated Jul 23, 2026

Identification of Biomarkers of Obstructive Sleep Apnea.

An interventional study of Positive Airway Pressure (PAP) Therapy in Obstructive Sleep Apnea, Obstructive Sleep Apnea (OSA) and Obstructive Sleep Apnea (OSAS), sponsored by Medical University of Bialystok. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Medical University of Bialystok · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Dec 2025, registered Jul 2026).
  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Sleep Apnea, Obstructive with a site in Poland — 6 open to participants now, 8 under way, 4 of them phase 3. Sleep Apnea, Obstructive · Poland.

Started
2025
with 4 others
No phase
4 of 13
1 open now
Registered
13th of 13
by date
Lead sponsor
2 of 13
Medical University of Bialystok

Among the 13 studies in Sleep Apnea, Obstructive with a site in Poland, this one is one of 5 that started in 2025, is one of 4 with no phase, and was the 13th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

6 of the 13 studies in Sleep Apnea, Obstructive with a site in Poland are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Sleep Apnea, Obstructive with a site in Poland, or all of them as a file.
02

Study summary

Obstructive sleep apnea (OSA) is a common sleep disorder associated with intermittent hypoxia, systemic inflammation, oxidative stress, and an increased risk of cardiovascular and metabolic diseases. Current diagnostic methods are effective but have limited availability and do not adequately predict disease burden or treatment response.

The purpose of this study is to identify and validate blood biomarkers that may improve the screening, diagnosis, risk stratification, and monitoring of adults with OSA. A total of 120 participants will undergo clinical evaluation and overnight polysomnography. Participants with moderate-to-severe OSA will be randomly assigned to either immediate or delayed positive airway pressure (PAP) therapy, while participants without OSA will serve as controls. Blood samples will be collected at predefined time points and analyzed for inflammatory, metabolic, oxidative stress, and other candidate biomarkers.

The study aims to determine which biomarkers are associated with OSA severity and how they change in response to PAP therapy. The results may contribute to the development of more accessible and personalized diagnostic and monitoring strategies for patients with OSA.

Read the detailed description

Obstructive sleep apnea (OSA) is a highly prevalent disorder characterized by recurrent upper airway obstruction during sleep, resulting in intermittent hypoxia, sleep fragmentation, oxidative stress, systemic inflammation, endothelial dysfunction, and metabolic disturbances. Untreated OSA is associated with an increased risk of cardiovascular disease, diabetes mellitus, stroke, impaired quality of life, and all-cause mortality. Despite the availability of polysomnography as the reference diagnostic method, current diagnostic approaches have limited accessibility and do not adequately reflect disease burden or predict treatment response.

The primary objective of this study is to identify and validate blood biomarkers associated with the presence, severity, and treatment response of OSA. The investigators hypothesize that selected circulating proteins, inflammatory mediators, oxidative stress markers, and metabolic profiles can improve the screening, diagnosis, risk stratification, and monitoring of patients with OSA.

A total of 120 adults will undergo standardized clinical evaluation and overnight polysomnography. Participants diagnosed with moderate-to-severe OSA will be randomly assigned to either immediate or delayed initiation of positive airway pressure (PAP) therapy, whereas participants without OSA will serve as the control group. Blood samples will be collected at predefined study visits to evaluate changes in candidate biomarkers before and during treatment.

The study will investigate a broad panel of biomarkers representing inflammatory pathways, endothelial dysfunction, oxidative stress, and metabolomic alterations using validated laboratory techniques, including multiplex immunoassays, enzyme-linked immunosorbent assays (ELISA), and metabolomic analyses. Changes in biomarker profiles will be evaluated in relation to OSA severity and response to PAP therapy.

The results of this study are expected to improve the understanding of the biological mechanisms underlying OSA and facilitate the development of novel biomarker-based approaches for screening, diagnosis, disease monitoring, and personalized management of patients with obstructive sleep apnea.

03

Conditions studied

  • Obstructive Sleep Apnea
  • Obstructive Sleep Apnea (OSA)
  • Obstructive Sleep Apnea (OSAS)
  • Obstructive Sleep Apnea (SAOS)
  • Obstructive Sleep Apnea (Moderate to Severe)

Keywords

  • Obstructive sleep apnea
  • OSA
  • Positive airway pressure therapy
  • CPAP
  • Blood biomarkers
  • Polysomnography
  • Inflammation
  • Oxidative stress
  • Metabolomics
  • Precision medicine
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants with obstructive sleep apnea (OSA):

    • Age 18 to 65 years.
    • Moderate or severe obstructive sleep apnea confirmed by overnight polysomnography (apnea-hypopnea index [AHI] ≥15 events/hour).
    • Willing and able to provide written .
    • Willing to undergo repeated blood sampling and study assessments.
    • Willing to use positive airway pressure (PAP) therapy and accept random assignment to immediate or delayed treatment.
  2. Control participants:

    • Age 18 to 65 years.
    • No obstructive sleep apnea (AHI \<5 events/hour on overnight polysomnography).
    • Willing and able to provide written informed consent.
    • Willing to undergo study assessments and blood sampling.

Exclusion criteria

Exclusion Criteria:

  • Mild obstructive sleep apnea (AHI 5 to \<15 events/hour).
  • Central sleep apnea.
  • Previous treatment for obstructive sleep apnea within the previous 3 months.
  • (BMI) ≥40 kg/m².
  • Severe cardiovascular disease.
  • Severe kidney disease or impaired renal function.
  • Significant liver disease.
  • Chronic inflammatory, , or rheumatic disease.
  • Active cancer or other condition associated with systemic inflammation.
  • Chronic respiratory diseases, including asthma or .
  • Respiratory infection within 4 weeks before enrollment.
  • Major surgery or significant injury within the previous 3 months.
  • Chronic rhinosinusitis.
  • Current treatment with systemic , drugs, cytotoxic drugs, chronic anti-inflammatory medications, or other medications that may influence inflammatory biomarkers.
  • Pregnancy or any condition that, in the opinion of the investigators, would make participation unsafe or interfere with interpretation of the study results.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Early Positive Airway Pressure (PAP) Therapy

    Participants with moderate-to-severe obstructive sleep apnea receive positive airway pressure (PAP) therapy immediately after randomization and continue treatment for 6 months. Clinical assessments and blood samples are obtained at baseline, 3 months, and 6 months.

    Device: Positive Airway Pressure (PAP) Therapy

  • Experimental
    Delayed Positive Airway Pressure (PAP) Therapy

    Participants with moderate-to-severe obstructive sleep apnea do not receive PAP therapy during the first 3 months after randomization. PAP therapy is initiated after the 3-month evaluation and continued for the following 3 months. Clinical assessments and blood samples are obtained at baseline, 3 months, and 6 months.

    Device: Positive Airway Pressure (PAP) Therapy

  • No intervention
    Control Group

    Participants without obstructive sleep apnea undergo baseline clinical evaluation, overnight polysomnography, and blood sampling. No PAP therapy or study intervention is administered.

Interventions

  • DevicePositive Airway Pressure (PAP) Therapy

    Positive airway pressure (PAP) therapy will be administered according to current clinical practice guidelines for the treatment of obstructive sleep apnea. PAP settings will be individually titrated based on clinical assessment and sleep study findings to ensure effective treatment. Participants assigned to PAP therapy will use the device during sleep for the duration specified in the study protocol. Adherence to therapy will be monitored using device-recorded usage data.

06

What researchers measure

Primary outcomes

  1. Difference in blood biomarker concentrations between participants with obstructive sleep apnea (OSA) and non-OSA controls at baseline

    Comparison of baseline serum and plasma concentrations of a predefined panel of circulating protein biomarkers (osteoprotegerin, cardiotrophin-1, chitinase-3-like protein 1/YKL-40, CRP, HbA1c, erythropoietin, thioredoxin, PD-L1) and a predefined multiplex panel of 48 cytokines, chemokines and growth factors, measured by ELISA and multiplex ELISA (Luminex), between adults with moderate-to-severe OSA (AHI \>=15) and non-OSA controls (AHI \<5) defined by polysomnography. Results will be reported in assay-appropriate units, including pg/mL, ng/mL, mg/L, or percentage, as applicable.

    Time frame: At enrollment, prior to initiation of PAP therapy (baseline, Month 0).

  2. Change in blood biomarker concentrations in OSA participants after positive airway pressure (PAP) therapy.

    Change from baseline in serum and plasma concentrations of the predefined biomarker panel after positive airway pressure (PAP) therapy. In the Early Treatment Group change is assessed after 3 and 6 months of continuous PAP; in the Delay-TG after 3 months of PAP delivered between months 3 and 6. Aim: determine whether and to what degree biomarker values change in response to standard OSA treatment.

    Time frame: Baseline, 3 months and 6 months.

Secondary outcomes

  1. Correlation between baseline blood biomarker concentrations and OSA severity (AHI)

    Correlation between baseline concentrations of the studied blood biomarkers and OSA severity expressed by the apnea-hypopnea index (AHI), as well as mean and lowest nocturnal oxygen saturation, in OSA participants. Goal: evaluate suitability of biomarkers for grading OSA severity.

    Time frame: At enrollment, prior to initiation of PAP therapy (baseline, Month 0).

  2. Normalization of blood biomarker concentrations toward control values after PAP therapy in OSA participants.

    Comparison of post-PAP-treatment biomarker concentrations in OSA participants (Early-TG and Delay-TG) with the enrollment values of the non-OSA control group, to assess whether treatment shifts biomarker values toward those of healthy controls. Goal: identify biomarkers specific to OSA-related hypoxia that approach the concentrations observed in participants without OSA.

    Time frame: Control: baseline; Early-TG: Month 3 and Month 6; Delay-TG: Month 6.

  3. Effect of PAP treatment duration (3 vs 6 months) on blood biomarker concentrations

    Assessment of the impact of PAP treatment duration on biomarker values: (a) comparison of post-treatment values between the Early Treatment Group (6 months of PAP) and the Delay Treatment Group (3 months of PAP); (b) within Early-TG, comparison of values after 3 versus 6 months to evaluate whether changes become more robust with continued treatment. Goal: determine whether longer therapy produces greater biomarker change.

    Time frame: 3 months and 6 months

  4. Stability of blood biomarker concentrations in untreated OSA (3-month observation period).

    Comparison of biomarker concentrations in the Delay-TG between baseline and after the 3-month observation period without any treatment, to verify that biomarker values do not change spontaneously in the absence of PAP therapy. Serves as the internal untreated reference for the treatment effect.

    Time frame: Baseline and 3 months (Delay-TG)

  5. Differences in serum and plasma metabolomic profiles between OSA and controls and in response to PAP therapy.

    Targeted and untargeted metabolomic profiling (GC-MS and LC-QTOF-MS; amino acids, carbohydrates, fatty acids, and specific lipids including phosphatidylcholines, ceramides, triglycerides and lysophosphatidylcholines) compared between OSA participants and controls at baseline, and before versus after PAP therapy in OSA participants. Goal: identify known and novel metabolite biomarkers of OSA.

    Time frame: Baseline, 3 months and 6 months

Other outcomes

  1. Differences in blood biomarker concentrations between moderate and severe OSA subgroups.

    Comparison of biomarker concentrations between participants with moderate OSA (15\<=AHI\<30) and severe OSA (AHI\>=30) at baseline and in response to PAP therapy.

    Time frame: Baseline, 3 months and 6 months

  2. Differences in blood biomarker concentrations between BMI categories (normal weight, overweight, obese).

    Comparison of biomarker concentrations between body-mass-index categories (normal \<25, overweight 25-\<30, obese \>=30) at baseline and in response to PAP therapy, to assess whether biomarker profile and treatment response differ by weight category.

    Time frame: Baseline, 3 months and 6 months

  3. Differences in blood biomarker concentrations between female and male participants.

    Comparison of biomarker concentrations between female and male participants at baseline and in response to PAP therapy, to assess sex-related differences in biomarker profile and treatment response.

    Time frame: Baseline, 3 months and 6 months

  4. Concentrations of oxidative stress biomarkers in OSA participants and controls

    Assessment of protein, lipid and DNA oxidation products: advanced oxidation protein products (AOPP, colorimetric method), ischemia-modified albumin, advanced glycation end products, 3-nitrotyrosine, 4-hydroxynonenal, 8-isoprostanes and 8-hydroxy-2-deoxyguanosine (ELISA), compared between OSA and controls at baseline and before versus after PAP therapy.

    Time frame: Baseline, 3 months and 6 months

07

Study locations

1 of 1 sites recruiting
  • Department of Otolaryngology, Medical University of Bialystok
    Bialystok, Podlaskie Voivodeship 15-276, Poland
    Recruiting
08

References and documents

Publications

  • Olszewska E, Pietrewicz TM, Swiderska M, Jamiolkowski J, Chabowski A. A Case-Control Study on the Changes in High-Sensitivity C-Reactive Protein and Tumor Necrosis Factor-Alpha Levels with Surgical Treatment of OSAS. Int J Mol Sci. 2022 Nov 15;23(22):14116. doi: 10.3390/ijms232214116. PubMed 36430593 ↗
  • Mohit, Tomar MS, Araniti F, Pateriya A, Singh Kushwaha RA, Singh BP, Jurel SK, Singh RD, Shrivastava A, Chand P. Identification of metabolic fingerprints in severe obstructive sleep apnea using gas chromatography-Mass spectrometry. Front Mol Biosci. 2022 Nov 21;9:1026848. doi: 10.3389/fmolb.2022.1026848. eCollection 2022. PubMed 36504723 ↗
  • Kheirandish-Gozal L, Gozal D. Obstructive Sleep Apnea and Inflammation: Proof of Concept Based on Two Illustrative Cytokines. Int J Mol Sci. 2019 Jan 22;20(3):459. doi: 10.3390/ijms20030459. PubMed 30678164 ↗
  • Olszewska E, De Vito A, Heiser C, Vanderveken O, O'Connor-Reina C, Baptista P, Kotecha B, Vicini C. Consensus Statements among European Sleep Surgery Experts on Snoring and Obstructive Sleep Apnea: Part 3 Palatal Surgery, Outcomes and Follow-Up, Complications, and Post-Operative Management. J Clin Med. 2024 Sep 13;13(18):5438. doi: 10.3390/jcm13185438. PubMed 39336926 ↗
  • Olszewska E, De Vito A, O'Connor-Reina C, Heiser C, Baptista P, Kotecha B, Vanderveken O, Vicini C. Consensus Statements among European Sleep Surgery Experts on Snoring and Obstructive Sleep Apnea: Part 2 Decision-Making in Surgical Management and Peri-Operative Considerations. J Clin Med. 2024 Apr 3;13(7):2083. doi: 10.3390/jcm13072083. PubMed 38610848 ↗
  • Olszewska E, De Vito A, Baptista P, Heiser C, O'Connor-Reina C, Kotecha B, Vanderveken O, Vicini C. Consensus Statements among European Sleep Surgery Experts on Snoring and Obstructive Sleep Apnea: Part 1 Definitions and Diagnosis. J Clin Med. 2024 Jan 16;13(2):502. doi: 10.3390/jcm13020502. PubMed 38256636 ↗
  • Olszewska E, Woodson BT. Palatal anatomy for sleep apnea surgery. Laryngoscope Investig Otolaryngol. 2019 Jan 10;4(1):181-187. doi: 10.1002/lio2.238. eCollection 2019 Feb. PubMed 30828637 ↗
  • Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, Nunez CM, Patel SR, Penzel T, Pepin JL, Peppard PE, Sinha S, Tufik S, Valentine K, Malhotra A. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019 Aug;7(8):687-698. doi: 10.1016/S2213-2600(19)30198-5. Epub 2019 Jul 9. PubMed 31300334 ↗
  • Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013 May 1;177(9):1006-14. doi: 10.1093/aje/kws342. Epub 2013 Apr 14. PubMed 23589584 ↗
  • Olszewska, E., Chrapanie i Bezdechy. Diagnostyka i Leczenie [Snoring and Apnea. Diagnosis and Treatment] 2019, Warszawa: Medipage

Individual participant data

Plan to share: Undecided — The individual participant data sharing plan has not yet been determined. A final decision will be made after study completion in accordance with institutional policies, ethical approvals, and applicable regulations.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jun 2029, 42 months after the start.

Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 42 months is above that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2026
First posted
Jul 23, 2026
StartActual
Dec 19, 2025
Primary completionEst.
Jun 19, 2029
CompletionEst.
Jun 19, 2029
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07723144
Lead sponsor
Medical University of Bialystok
Collaborators
National Science Centre, Poland
Responsible party
Sponsor
First posted
Jul 23, 2026
Start date
Dec 19, 2025
Primary completion
Jun 19, 2029 (estimated)
Completion
Jun 19, 2029 (estimated)
Last update
Jul 23, 2026

Study contacts

Ewa Olszewska, M.D., Prof.
Contact
ewa.olszewska@umb.edu.pl
+48 85 831 82 69
Agnieszka Polecka, M.D.
Contact
agnieszka.polecka@umb.edu.pl
+48 85 831 82 69

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion